Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

MH370 families launch campaign to fund search for the missing jet

Mar 4, 2017

US-MALAYSIA-AIRLINES:MH370 families launch campaign to fund search for the missing jet

Altice U.S. cable growth a priority as it explores wireless: founder

May 23, 2017

US-ALTICE-WIRELESS:Altice U.S. cable growth a priority as it explores wireless: founder

Past repackaged: EU plan for Balkan market faces resistance

Apr 7, 2017

US-BALKANS-EU-MARKET:Past repackaged: EU plan for Balkan market faces resistance

Must Read

MH370 families launch campaign to fund search for the missing jet

Mar 4, 2017

US-MALAYSIA-AIRLINES:MH370 families launch campaign to fund search for the missing jet

Altice U.S. cable growth a priority as it explores wireless: founder

May 23, 2017

US-ALTICE-WIRELESS:Altice U.S. cable growth a priority as it explores wireless: founder

Past repackaged: EU plan for Balkan market faces resistance

Apr 7, 2017

US-BALKANS-EU-MARKET:Past repackaged: EU plan for Balkan market faces resistance

Search
You May Need To Know

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales@obserworld.com